AstraZeneca in cancer viruses deal with Omnis Pharmaceuticals
LONDON (Reuters) - AstraZeneca said on Monday its MedImmune biotech unit had struck a deal with unlisted U.S. company Omnis Pharmaceuticals on the development of cancer-fighting oncolytic viruses.
No comments:
Post a Comment